Otezla generic
Otezla is an anti-inflammatory drug owned by Amgen Inc. It contains the active ingredient apremilast and was first authorized for market use on 21st March 2014. The drug comes in a tablet form for oral administration and holds a total of 11 patents, with 8 already expired.
When will Otezla generic be available?
The Otezla generic is set to be available after 29th May 2034. This date corresponds to the expiry of the patent US9872854, which covers methods for the treatment of psoriatic arthritis using Apremilast. This is the last patent held by the drug and determines the earliest possible date for generic production.
Otezla uses
Otezla is used for the treatment of several skin and joint disorders. Its active ingredient, apremilast, contributes to its effectiveness by inhibiting phosphodiesterase 4 (PDE4), a cellular enzyme. This inhibition results in a decreased inflammation response. Specific uses include the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behcet's disease. Some treatment schedules also involve using Otezla in combination with a second active agent.
Otezla patent expiration
Otezla holds 11 patents in total, with 8 already expired. The last effective patent, US9872854, covering the usage of Apremilast for the treatment of psoriatic arthritis, will expire on 29th May 2034. Post this date, Otezla generic could possibly hit the market. Below are the details of the patent: